Immune responses in cancer

Pharmacology and Therapeutics

Volumn 99, Issue 1, 2003, Pages 113-132

  Adam, Jamila K ^a   Odhav, Bharti ^a   Bhoola, Kanti D ^b  

^a DURBAN UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Carcinogenesis; Immunity; Immunotherapy; Tumour antigens and surveillance; Vaccines

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CHEMOKINE; COLONY STIMULATING FACTOR; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMORAL ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOKINE; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ANTIGEN RECOGNITION; ANTIGENICITY; APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CELL CYCLE; CELL INVASION; CELL POPULATION; CELL PROLIFERATION; CELL TRANSFORMATION; DNA REPLICATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; METASTASIS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ESCAPE; UPREGULATION; VACCINATION;

EID: 0038120144     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00056-1     Document Type: Article

References (123)

1. Adler H.L., McCurdy M.A., Kattan M.W., Time T.L., Scardino P.T., Thompson T.C. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 61:1999;182-187.
2. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomized, multicenter trial of interferon alfa n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 345:1995;1392-1397.
3. Arend W.P. IL-1 receptor antagonist. Adv Immunol. 54:1993;167-227.
4. Arend W.P., Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33(3):1990;305-315.
5. Atkins M.B., Roberston M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., Ritz J., Sandler A.B., Edington H.D., Garzone P.D., Mier J.W., Canning C.M., Battiato L., Tahara H., Sherman M.L. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res. 3:1997;409-417.
6. Attardi L.D., Reczek E.E., Cosmas C., Demicco E.G., McCurrach M.E., Lowe S.W., Boise H.L., Gonzales-Garcia M., Postema E.C., Ding L., Lindstein T., Turka A.L., Mao X., Nunez G., Thompson C.B. Bcl-x, a Bcl-2 related gene that function as a domain regulator of apoptotic cell death. Cell. 74:1993;597-608.
7. Atzpodien J., Hoffmann R., Franzke M., Stief C., Wandert T., Reitz M. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer. 95(5):2002;1045-1050.
8. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 84:1989;1045-1049.
9. Baggiolini M., Deward B., Moser B. Interleukin-8 and related chemotactic cytokines - CVC and CC chemokines. Adv Immunol. 55:1994;97-179.
10. Baker P.K., Pettitt A.R., Slupsky J.R., Chen H.J., Glenn M.A., Zuzel M., Cawley J.C. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood. 100(2):2002;647-653.
11. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 196(3):2002;254-265.
12. Bodey B. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther. 2(6):2002;577-584.
13. Brennan F.M., Maini R.N., Feldmann M. TNF-alpha - a pivotal role in rheumatoid arthritis? Br J Rheumatol. 31:1992;293-298.
14. Bukowski R., Ernstoff M.S., Gore M.E., Nemunaitis J.J., Amato R., Gupta S.K., Tendler C.L. Pegylated interferon alfa-2b treatment for patients with solid tumours: a phase I/II study. J Clin Oncol. 20(18):2002;3841-3849.
15. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res. 13:1970;1-4.
16. Cannon M.J., O'Brien T.J., Underwood L.J., Crew M.D., Bondurant K.L., Santin A.D. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2(1):2002;97-105.
17. Chen H.W., Huang H.I., Lee Y.P., Chen L.L., Liu H.K., Cheng M.L., Tsai J.P., Tao M.H., Ting C.C. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment. Cancer Immunol Immunother. 51(6):2002;341-348.
18. Clark E.A., Ledbetter J.A. How B and T cells talk to each other. Nature. 367:1994;425-428.
19. Clement M.V., Legros-Maida S., Israel-Biet D., Carnot F., Soulie A., Reynaud P., Guillet J., Gandjbakch I., Sasportes M. Perforin and granzyme B expression is associated with severe acute rejection. Evidence for in situ localization in alveolar lymphocytes of lung-transplanted patients. Transplantation. 57:1994;322-326.
20. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J. 326:1997;1-16.
21. Coleman R.M., Lombard M.F., Sicard R.E. Tumour immunology. Fundamental Immunology. 2nd ed. 1992;460-483 W.M.C. Brown.
22. Coley W.B. The treatment of malignant tumours by repeated inoculations of erysipelas. With a report of ten original cases, 1893. Clin Orthop. 262:1991;3-11.
23. Conry R.M., Khazaeli M.B., Saleh M.N., Allen K.O., Barlow D.L., Moore S.E., Craig D., Arani R.B., Schlom J., LoBuglio A.F. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinomas: comparison of intradermal versus subcutaneous administration. Clin Cancer Res. 5:1999;2330-2337.
24. Dallman M.J. Cytokines and transplantation: Th1/ Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol. 7:1995;632-638.
25. Dermime S., Armstrong A., Hawkins R.E., Stern P.L. Cancer vaccines and immunotherapy. Br Med Bull. 62:2002;149-162.
26. Dey B.R., Sukhatme V.P., Roberts A.B., Sporn M.B., Rauscher F.J., Kim S.J. Repression of the transforming growth factor beta 1 gene by the Wilms' tumour suppressor WT1 gene product. Mol Endocrinol. 8:1994;595-602.
27. Dinarello C.A. The biological properties of interleukin-1. Eur Cytokine Netw. 5:1994;517-531.
28. Dinarello C.A., Cannon J.G., Mier J.W., Bernheim H.A., LoPreste G., Lynn D.I., Love R.N., Weblo A.C., Auron P.E., Reuben R.C., Rich A., Wolff S.M., Putney S.C. Multiple biological activities of human recombinant interleukin-1. J Clin Invest. 77:1986;1734-1739.
29. Dorval T., Palangie T., Jouve M., Garcia-Giralt E., Falcoff E., Schwab D., Lerminier M., Pouillart P. Treatment of metastatic melanoma with recombinant interferon alfa-2b. Invest New Drugs. 5:1987;S61-S63.
30. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 188(1):2002;147-154.
31. Earnshaw W.C., Martins L.M., Kaufman S.H. Mammalian caspase: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 68:1999;383-424.
32. Espinoza-Delgado I. Cancer vaccines. Oncologist. 7(2):2002;20-33.
33. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature. 411:2001;4342-4348.
34. Fabian Z., Torocsik B., Kiss K., Csatary L.K., Bodey B., Tigyi J., Csatary C., Szeberenyi J. Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res. 21(1A):2001;125-135.
35. Firestein G.S. Rheumatoid arthritis: rheumatoid synovitis and pannus. Klippel J.A., Dieppe P.A. Rheumatology. 1994;3.12.1-3.12.30 Mosby-Year Book Europe.
36. Fischer H.G., Frosch S., Reske K., Reske-Kunz A.B. Granulocyte macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol. 141:1988;3883-3888.
37. Galea H.R., Cogne M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exp Immunol. 129(2):2002;247-253.
38. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 109(81-96):2002;581.
39. Gough M.J., Melcher A.A., Ahmed A., Crittenden M.R., Riddle D.S., Linardakis E., Ruchatz A.N., Emiliusen L.M., Vile R.G. Macrophages orchestrate the immune response to tumor cell death. Cancer Res. 61(19):2001;7240-7247.
40. Gowans J.L., McGregor D., Collen D.M., Ford C.E. Initiation of immune response by small lymphocytes. Nature. 196:1962;651-665.
41. Gri G., Chiodoni C., Gallo E., Stoppacciaro A., Liew F.Y., Colombo M.P. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 62(15):2002;4390-4397.
42. Griffiths G.J., Dubrez L., Morgan C.P., Jones N.A., Whitehouse J., Corfe B.M., Dive C., Hickman J.A. Cell damage-induced conformational changes of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol. 144:1999;903-914.
43. Groopamn J.E., Molina J.M., Seadden D.T. Hematopoietic growth factors. N Engl J Med. 321:1989;1449-1459.
44. Grossman Z., Herberman R.B. Immune surveillance without immunogenecity. Immunol Today. 7:1986;128-131.
45. Gupta S., Kanodia A.K. Biological response modifiers in cancer therapy. Natl Med J India. 15(4):2002;202-207.
46. Hamilton T.A., Adams D.O. Molecular mechanisms of signal transduction in macrophage activation. Immunol Today. 8:1987;151-158.
47. Hanna M.G. Jr., Hoover H.C. Jr., Vermorken J.B., Harris J.E., Pinedo H.M. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumour cell vaccine: first randomized phase III trials show promise. Vaccine. 19:2001;2576-2582.
48. Heidenreich S., Gong J.H., Schmidt A., Nain M., Gemsa D. Macrophage activation by granulocyte/macrophage colony stimulating factor. Priming for enhanced release of tumour necrosis factor-alpha and prostaglandin E2. J Immunol. 143:1989;1198-1205.
49. Hsueh E.C., Famatiga E., Gupta R.K., Qi K., Morton D.L. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol. 5:1998;595-602.
50. Hwang C., Sanda M.G. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr Opin Mol Ther. 1(4):1999;471-479.
51. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 99(19):2002;12293-12297.
52. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L., Yeo C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumour vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 19:2001;145-156.
53. Jager D., Jager E., Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol. 54(9):2001;675-676.
54. Jager D., Jager E., Knuth A. Vaccination for malignant melanoma: recent developments. Oncology. 60(1):2001;1-7.
55. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 14:1996;7-17.
56. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., Blum R.H. High and low-dose interferon alfa-2b in high-risk melanoma: first analysis of inter-group trial E1690/S9111/C9190. J Clin Oncol. 18:2000;2444-2458.
57. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of an inter-group trial E1694/S9512/C509801. J Clin Oncol. 19:2001;2370-2380.
58. Kobayashi H., Wood M., Song Y., Appella E., Celis E. Defining promiscuous MHC class II helper T cell epitopes for the HER-2/neu tumour antigen. Cancer Res. 60:2000;5228-5236.
59. Krensky A.M., Weiss A., Crabtree G., Davis M.M., Parham P. T lymphocyte-antigen interactions in transplant rejection. N Engl J Med. 322:1990;510-517.
60. Kulcsar G. Apoptosis of tumor cells induced by substances of the circulatory system. Cancer Biother Radiopharm. 12(1):1997;19-26.
61. Kulcsar G. Theoretical and literary evidence for the existence of the passive antitumor defence system. Cancer Biother Radiopharm. 12(4):1997;281-286.
62. Kusumoto M., Umeda S., Ikubo A., Aoki Y., Tawfik O., Oben R., Williamson S., Jewell W., Suzuki T. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF. Cancer Immunol Immunother. 50:2001;373-381.
63. Lauerova L., Dusek L., Simickova M., Kocak I., Vagundova M., Zaloudik J., Kovarik J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 49(3):2002;159-166.
64. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S., Gee C., Lau R., Jeffery G., Margolin K., Marty V., Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol. 19:2001;3836-3847.
65. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
66. Lewis C.E., McGee J.O.D. The Natural Immune System: The Macrophage. 1992;IRS, Oxford, UK.
67. Li C., Thompson C.B. Cancer. DNA damage, deamidation, and death. Science. 298(5597):2002;1346-1347.
68. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2(10):2002;725-734.
69. Liu Y., Zhang W., Chan T., Saxena A., Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 26(8):2002;757-763.
70. Lorenzo J.A. The role of cytokines in the regulation of local bone resorption. Crit Rev Immunol. 11:1991;195-213.
71. Malumbres M., Barbacid M. Milestones in cell division: to cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 1:2001;222-231.
72. Marshall J.L., Hoyer R.J., Toomey M.A., Faraguna K., Chang P., Richmond E., Pedicano J.E., Gehan E., Peck R.A., Arlen P., Tsang K.Y., Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 18:2000;3964-3973.
73. Mason D.W. Subpopulations of T lymphocytes. Immunol Lett. 14:1987;269-270.
74. Mason D.W. The role of T cell subpopulations in allograft rejection. Transplant Proc. 20:1988;239-242.
75. Mason D.W., Morris P.J. Effector mechanisms in allograft rejection. Annu Rev Immunol. 4:1986;119-145.
76. Medawar P.B. The behaviour and fate of skin allografts and skin homografts in rabbits. J Anat. 79:1944;158-176.
77. Miceli M.C., Parnes J.R. The roles of CD4 and CD8 in T cell activation. Semin Immunol. 3(3):1991;133-141.
78. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., Meryman H.T. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 38:2000;208-217.
79. Modak S., Gerald W., Cheung N.K. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol. 39(6):2002;547-551.
80. Morse M.A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., Schlom J., Ryback M.E., Lyerly H.K. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 5:1999;1331-1338.
81. Naglieri E., Lopez M., Lelli G., Morelli F., Amodio A., Di Tonno P., Gebbia N., Di Seri M., Chetri M.C., Rizzo P., Abbate I., Casamassima A., Selvaggi F.P., Colucci G. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res. 22(5):2002;3045-3051.
82. Nawrocki S., Wysocki P.J., Mackiewicz A. Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin Biol Ther. 1(2):2001;193-204.
83. Nicklin M.J.H., Weith A., Duff G.W. A physical map of the region encompassing the human interleukin-1α, interleukin-1β, and interleukin-1 receptor antagonist genes. Genomics. 19:1994;382-384.
84. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 23(2-3):2001;263-272.
85. Oka Y., Tsuboi A., Elisseeva O.A., Udaka K., Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets. 2(1):2002;45-54.
86. Old L.J. Immunotherapy for cancer. Sci Am. 275:1996;136-143.
87. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18(49):1999;6853-6866.
88. Paulnock D.M. Macrophage activation by T cells. Curr Opin Immunol. 4:1992;344-349.
89. Peipp M., Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans. 30(4):2002;507-511.
90. Plunkett T.A., Miles D.W. New biological therapies for breast cancer. Int J Clin Pract. 56(4):2002;261-266.
91. Quesada J.R., Hersh E.M., Manning J., Reuben J., Keating M., Schnipper E., Itri L., Gutterman J.U. Treatment of hairy cell leukemia with recombinant alfa-interferon. Blood. 68:1986;493-497.
92. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 110(1):2002;71-79.
93. Ravaud A., Delva R., Gomez F., Chevreau C., Douillard J.Y., Peny J., Coudert B., Negrier S. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma - less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Francais d'Immunotherapie. Cancer. 95(11):2002;2324-2330.
94. Rini B.I., Weinberg V., Bok R., Small E.J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 21(1):2003;99-105.
95. Rossi V., Breviario F., Ghenzzi P., Dejana E., Mantovani A. Prostacylin synthesis induced in vascular cells by interleukin-1. Science. 229:1985;1174-1176.
96. Sato K., Torimoto Y., Tamura Y., Shindo M., Shinzaki H., Hirai K., Kohgo Y. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood. 98(6):2001;1852-1857.
97. Scaffidi C., Kirchhoff S., Krammer P.H., Peter E.M. Apoptosis signaling in lymphocytes. Curr Opin Immunol. 11:1999;277-285.
98. Schirrmacher V., Griesbach A., Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol. 18(5):2001;945-952.
99. Schmitt D. The Langerhans cell: from in vitro production to use in cellular immunotherapy. J Soc Biol. 195(1):2001;69-74.
100. Schneider T., Gerhards R., Kirches E., Firsching R. Preliminary results of active specific immunization with modified tumour cell vaccine in glioblastoma multiforms. J Neuro-oncol. 53:2001;39-46.
101. Segal J.G., Lee N.C., Tsung Y.L., Norton J.A., Tsung K. The role of IFN-gamma in rejection of established tumors by IL-12: source of production and target. Cancer Res. 62(16):2002;4696-4703.
102. Senderowicz A.M. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Cancer Chemother Biol Response Modif. 19:2001;165-188.
103. Sims J.E., Dower S.K. Interleukin-1 receptors. Eur Cytokine Netw. 5:1994;539-546.
104. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 344:2001;783-792.
105. Smith C.L., Dulphy N., Salio M., Cerundolo V. Immunotherapy of colorectal cancer. Br Med Bull. 64:2002;181-200.
106. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2(11):2002;850-861.
107. Strieter R.M., Kasahara K., Allen R.M., Standiford T.J., Rolfe M.W., Becker F.S., Chensue S.W., Kunkel S.L. Cytokine-induced neutrophil derived interleukin-8. Am J Pathol. 141:1992;397-407.
108. Stripecke R., Levine A.M., Pullarkat V., Cardoso A.A. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia. 16(10):2002;1974-1983.
109. Termeer C.C., Schirrmacher V., Brocker E.B., Becker J.C. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 7(2):2000;316-323.
110. Tilney N.L., Garovoy M.R., Busch G.J. Rejected human renal allografts: recovery and characteristics of infiltrating cells and antibody. Transplantation. 28:1979;421-426.
111. Titu L.V., Monson J.R., Greenman J. The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol Immunother. 51(5):2002;235-247.
112. Trauth B.C., Klas C., Peters A.M.J., Matzku S., Moler P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumour regression by induction of apoptosis. Science. 245:1989;301-305.
113. Uekusa Y., Gao P., Yamaguchi N., Tomura M., Mukai T., Nakajima C., Iwasaki M., Takeuchi N., Tsujimura T., Nakazawa M., Fujiwara H., Hamaoka T. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J Leukoc Biol. 72(5):2002;864-873.
114. van den Eynde B. Identification of cancer antigens of relevance for specific cancer immunotherapy. Bull Mem Acad R Med Belg. 156(10-12):2002;548-555.
115. von Mehren M., Arlen P., Gulley J., Rogatko A., Cooper H.S., Meropol N.J., Alpaugh R.K., Davey M., McLaughlin S., Beard M.T., Tsang K.Y., Schlom J., Weiner L.M. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 7:2001;1181-1191.
116. Wang R.F., Zeng G., Johnston S.F., Voo K., Ying H. T cell-mediated immune responses in melanoma: implications for immunotherapy. Crit Rev Oncol Hematol. 43(1):2002;1-11.
117. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother. 51(7):2002;351-357.
118. Weiss A., Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell. 76:1994;263-274.
119. Wilson D.R. Viral-mediated gene transfer for cancer treatment. Curr Pharm Biotechnol. 3(2):2002;151-164.
120. Wong G.G., Clark S.C. Multiple actions of interleukin 6 within a cytokine network. Immunol Today. 9(5):1988;137-139.
121. Xu W.D., Firestein G.S., Taetle R., Kaushansky K., Zvaifler N.J. Cytokines in chronic inflammatory arthritis: II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. 83:1989;876-882.
122. Yei S., Bartholomew R.M., Pezzoli P., Gutierrez A., Gouveia E., Bassett D., Soo Hoo W., Carlo D.J. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther. 9(19):2002;1302-1311.
123. Zinzani P.L., Lauria F., Salvucci M., Rondelli D., Raspadori D., Bendandi M., Magagnoli M., Tura S. Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Haematologica. 82(2):1997;152-155.